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Abstract
PKD2 is mutated in 15% of patients with autosomal dominant polycystic kidney disease (ADPKD).
Polycystin-2 (PC2), the PKD2 protein, is a nonselective Ca2+-permeable cation channel which may
function at the cell surface and ER. Nevertheless, the factors that regulate the dynamic translocation
of PC2 between the ER and other compartments are not well understood. Constitutive
phosphorylation of PC2 at a single C-terminal site (Ser812) has been previously reported. Since we
were unable to abolish phospholabelling of PC2 in HEK293 cells by site-directed mutagenesis of
Ser812 or all 5 predicted phosphorylation sites in the C-terminus, we hypothesised that PC2 could
also be phosphorylated at the N-terminus. In this paper, we report the identification of a new
phosphorylation site for PC2 within its N-terminal domain (Ser76) and demonstrate that this residue
is phosphorylated by glycogen synthase kinase 3 (GSK-3). The consensus recognition sequence for
GSK-3 (Ser76/Ser80) is evolutionarily conserved down to lower vertebrates. In the presence of
specific GSK-3 inhibitors, the lateral plasma membrane pool of endogenous PC2 redistributes into
an intracellular compartment in MDCK cells without a change in primary cilia localization. Finally,
co-injection of wild-type but not a S76A/S80A mutant PKD2 capped mRNA could rescue the cystic
phenotype induced by an antisense morpholino oligonucleotide to pkd2 in zebrafish pronephric
kidney. We conclude that surface localization of PC2 is regulated by phosphorylation at a unique
GSK-3 site in its N-terminal domain in vivo and in vitro. This site is functionally significant for the
maintenance of normal glomerular and tubular morphology.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited
human renal disease (incidence 1 in 1000 live births) and is caused by mutations in two genes,
PKD1 (85%) and PKD2 (15%). (1)ADPKD is an important cause of end-stage renal failure,
accounting for ∼10% of patients on renal replacement therapy. Typically, fluid-filled cysts
form in the kidney but cysts also commonly arise in the liver and pancreas. There is also an
increased incidence of non-cystic extrarenal manifestations in ADPKD such as cardiac valve
abnormalities, diverticular disease and intracranial aneurysms. (2)
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The ADPKD proteins, polycystin-1 (PC1) and polycystin-2 (PC2) are believed to function as
a complex, activating a number of key signalling pathways which in turn regulate diverse
cellular functions including proliferation, apoptosis, tubulogenesis and fluid secretion. (3)This
is consistent with the largely overlapping renal and extrarenal phenotypes of PKD1 and PKD2
patients. (3)PC1 may play a role in mediating cell adhesion or mechanosensation. (4,5)PC2
has been shown to function as a nonselective Ca2+-permeable cation channel, forming part of
the TRP (transient receptor potential) superfamily of channels which broadly function as
cellular sensors for multiple stimuli. (6,7)Although both proteins probably function together
as a heterodimeric complex, more recent work suggests that they can also function
independently of the other. (8,9)
Although PC1 is believed to act at the plasma membrane, the major site of action of PC2 has
been debated. Endogenous PC2 channel activity has been detected in the apical membrane of
placental syncytiotrophoblasts, primary cilia and the plasma membrane of cultured kidney cells
such as mIMCD3 and LLCPK. (10-13)Conversely, heterologous PC2 has been shown to
function as a calcium-activated ER calcium channel in LLCPK cells. (14)These findings could
be reconciled if PC2 is active at more than one subcellular location (e.g. ER, primary cilia,
plasma membrane).
Protein phosphorylation is an important post-translational mechanism known to regulate the
function of many proteins by affecting their assembly, retention, targeting, retrieval, activity
or half-life. (15)An effective means to control the activity of PC2 at the cell surface would be
to regulate its targeting, trafficking or retention between the ER, the primary cilia or lateral
plasma membrane. Recent work has suggested that PC2 is phosphorylated at residue Ser812 in
its C-terminus and that this event is important for its recognition and retrieval from the plasma
membrane to the Golgi and ER. (16,17)In this paper, we report the identification of an
alternative phosphorylation site within the N-terminus of PC2, and demonstrate that it is critical
for the function of PC2 at the plasma membrane both in vitro and in vivo.
Results
PC2 is phosphorylated at both its N- and C-termini
Sequence analysis of human PC2 by prediction programs including PhosphoBase, DISPHOS
1.3 and NetPhos show that it contains a large number of predicted phosphorylation sites within
both its N and C-terminal cytoplasmic domains. In agreement with a previous study, we were
able to demonstrate that PC2 is constitutively phosphorylated in vivo. (16)Endogenous PC2 in
mouse collecting duct cells was metabolically labelled with 32Pi - autoradiography of the
immunoprecipitated protein revealed a single band migrating at 110 kDa by SDS-PAGE which
was absent in the control lane (Fig. 1A). Immunoblotting of the same membrane with p30
confirmed that the phosphorylated protein was indeed PC2 (data not shown).
To determine the specific residues phosphorylated in PC2, we substituted alanine or glycine
at various combinations of five predicted phosphorylation sites within the C terminus,
Thr721, Ser801, Ser812, Ser831 and Ser943. (18)In addition, a naturally occurring truncation
mutant, R742X, which lacks most of the PC2 C-terminus but which does contain the Thr721
site was generated (Fig. 1B). In vivo phosphorylation analysis was performed by metabolic
labelling of transiently transfected HEK-293 cells (Fig. 1C). However, unlike a previous study,
we were unable to eliminate phosphorylation of PC2 by mutation of Ser812 (Fig. 1C) Moreover,
mutation of all 5 predicted sites within the C-terminus did not abolish phospholabelling though
a reduced level of phosphorylation was detected (Fig. 1C). R742X-PC2 also showed a reduced
level of phospholabelling (Fig. 1C). Although this contains the Thr721 residue, mutation of
Thr721 alone did not significantly alter PC2 phosphorylation, consistent with previous findings.
(16)
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These findings led us to hypothesize that PC2 could be phosphorylated within its N-terminal
domain. In the original report describing the cloning of PKD2, an N-terminal residue, Ser122,
was predicted to be a putative site for phosphorylation. (18)To investigate this further, the
entire N-terminal cytoplamic domain of PC2 (aa1-224) was first generated with an N-terminal
HA epitope tag for detection. Two additional constructs containing progressive truncations of
the PC2 N-terminus (aa1-178, aa1-118) were subsequently generated for further study (Fig.
1D). When L224X was transiently expressed in HEK-293 cells, a doublet band was
unexpectedly observed on western blotting using an HA epitope specific antibody (Fig. 1E,
upper panel). We speculated that the upper band represented a phosphorylated form of the
protein. Dephosphorylation with the enzyme, lambda phosphatase (which removes all
phosphate groups from serine, threonine or tyrosine residues) resulted in loss of the upper band
in a time dependent manner, confirming that the reduction in mobility on SDS-PAGE was
indeed the result of phosphorylation (Fig. 1E, upper panel). In vivo phospholabelling further
demonstrated that L224X could indeed be phosphorylated in HEK-293 cells (Fig. 1F).
Despite the prediction that an N-terminal residue, Ser122, might be the major site of
phosphorylation in the N-terminus, we observed phospholabelling of the smallest N-terminal
construct, W118X, which contains the first 118 amino acids of PC2, in HEK-293 cells (Fig.
1F). Once again, a doublet band was observed on immunoblotting which could be abolished
by lambda phosphatase treatment (Fig. 1E, lower panel). From these results, we concluded that
the major site of PC2 phosphorylation within its N-terminal cytoplasmic domain might lie
between amino acids 1 and 118.
GSK-3 mediates phosphorylation of the N-terminal of PC2 at Ser76
Using prediction programmes, a number of phosphorylation sites (Ser74, Ser76, Ser122,
Ser125) can be predicted within the N-terminus of PC2 though none have been previously
studied. To determine which of these sites might be phosphorylated (Fig 1E and F), we mutated
each of the residues shown in Fig 2A in L224X and analysed each mutant in turn as described
above. Mutation of Ser74, Ser122 or Ser125 did not affect phosphorylation of L224X as assessed
by doublet band formation (Fig 2B upper panel) or labelling with 32P (Fig 2B lower panel).
However, mutation of Ser76 to Ala76 resulted in a complete loss of labelling indicating it is the
major residue phosphorylated within the N-terminus of PC2 (Fig 2B).
Apart from HEK-293 cells, the PC2 N-terminal domain could be phosphorylated in a number
of cell lines including IMCD3, CHO-K1 and MDCK as assessed by doublet band formation
on immunoblotting (Fig. 2C). This phosphorylation was absent in cells transfected with a
Ser76 mutant construct (Fig. 2C). Ser76 in human PC2 is highly conserved in PC2 homologues
from higher and lower vertebrates suggesting that it has retained an important functional
significance throughout evolution (Fig. 2D). It forms part of a GSK-3 recognition sequence,
Ser/Thr-X-X-X-Ser/Thr, which is also fully conserved. This recognition sequence was
however not conserved in fly, worm or sea urchin PC2 homologues suggesting that the function
of PC2 is different in these lower organisms (data not shown).
To determine whether GSK-3 could directly phosphorylate the PC2 N-terminus, we expressed
L224X in HEK-293 cells in the presence or absence of four specific GSK-3 inhibitors (LiCl,
(2′Z,3′E)-6-Bromoindirubin-3′-oxime, SB 415286 and SB 216763). In each case, incubation
with the inhibitor resulted in the loss of the phosphorylated upper band (Fig. 2E).
Substrates of GSK-3 typically require a priming phosphorylation event at a serine or threonine
residue four bases downstream of the GSK-3 phosphorylation site (Fig. 2D). To determine
whether mutation of Ser80 had any effect on phosphorylation of the PC2 N-terminus, we
mutated it to an alanine and examined the effect on phosphorylation of L224X. As shown in
Fig 2F, the phosphorylated upper band was significantly reduced following mutation of
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Ser80. This suggests that Ser80 may be a priming phosphorylation site, which when absent,
significantly reduces the ability of GSK-3 to phosphorylate Ser76.
Inhibition of GSK-3 mediated PC2 phosphorylation alters its cellular localisation
To investigate the functional significance of GSK-3 phosphorylation of PC2 at Ser76, the effect
of GSK-3 inhibition on the subcellular localisation of endogenous PC2 was examined in the
polarised kidney cell line, MDCK. Cells were treated with either LiCl or SB 415286 for 16
hours and the distribution of endogenous PC2 and other well characterised adhesion junction
proteins examined by immunofluorescence (Fig 3A). In the presence of specific GSK-3
inhibitors, the lateral membrane pool of PC2 redistributed into an intracellular compartment
in MDCK cells with no change in its localisation in primary cilia (Fig 3A). In contrast, the
surface distribution of E-cadherin, ZO-1 and desmoplakin were unaffected after GSK-3
inhibition (Fig 3A). Similar results were seen in mIMCD3 cells and the mouse collecting duct
cell line, M8, though the surface membrane signals were variable between lines (not shown).
These results suggest that phosphorylation of PC2 by GSK-3 can affect its plasma membrane
localisation independent of its ciliary location.
Redistribution of PC2 from the cell surface into an intracellular compartment following GSK-3
inhibition was confirmed by cell surface biotinylation in mIMCD3 cells which express the
highest levels of PC2 (Fig 3B). mIMCD3 cells treated with SB 415286 showed a significant
reduction in expression of PC2 at the cell surface following GSK-3 inhibition (Fig 3B). By
densitometry, approximately 10% of total PC2 was present at the cell surface in control cells
compared with ∼ 1.5% after treatment with the inhibitor in 3 independent experiments. Similar
results were obtained in MDCK cells (Fig. 3B). Biotinylation of cell surface proteins was
shown to be specific as the ER resident protein calnexin was not biotinylated on reprobing of
the membrane (Fig 3B). Na+K+ATPase, a cell surface protein was strongly biotinylated but
was unaffected by treatment with the inhibitor (Fig 3B). These results confirm previous reports
that a small plasma membrane population of PC2 can be surface biotinylated in mIMCD3 and
MDCK cells. (12,19)
The phenotype induced by a pkd2 antisense morpholino oligonucleotide (pkd2ATGMO) in
zebrafish embryos can be rescued by wild type human PKD2 but not a PKD2 -S76A/S80A
mutant mRNA
Since the GSK-3 consensus sequence was conserved in zebrafish pkd2 (Fig. 2D), we reasoned
that phosphorylation at this site might be functionally important for nephrogenesis in this
organism. A pkd2ATGMO which has been shown to induce a cystic phenotype in zebrafish
embryos by blocking zebrafish pkd2 translation has been recently reported (20). Following
injection of pkd2ATGMO into embryos, pkd2 mRNA was not detected at 24 hpf (hours post
fertilisation) demonstrating that this MO effectively induces a null phenotype (data not shown).
Similar to a previous report (20), we found that injection of pkd2ATGMO into zebrafish
embryos (n=920) induced a characteristic phenotype at 72 hpf consisting of pronephric kidney
cysts, body axis curvature and hydrocephalus in 880 embryos (95.6%, Fig 4B). Cystic dilatation
of the pronephric tubules and glomeruli can be clearly seen in cross-section (Fig 4B). The
specificity of this null phenotype was confirmed by its complete rescue by the over-expression
of zebrafish pkd2 cDNA (data not shown), the lack of effect in 815 control MO injected
embryos (Fig 4A) and by the near-complete suppression of the pkd2ATGMO phenotype when
50pg human PKD2 mRNA was co-injected - 783 out of 812 embryos rescued (96.4%, Fig 4C).
In contrast, co-injection of 50pg human PKD2-S76A/S80A mutant mRNA could not rescue
the pronephric cysts and hydrocephalus caused by pkd2ATGMO although body axis curvature
was slightly rescued in the majority – 761 out of 792 embryos (96.1%, Fig 4D). The remaining
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31 embryos (3.9%) showed the same phenotype as with pkd2ATGMO indicating a complete
lack of rescue.
RT-PCR analysis using primers for the N-terminus of PKD2 confirmed expression of both
wild-type PKD2 and PKD2-S76A/S80A mRNA in the respective co-injected embryos (Fig
4E). PCR products were sequenced to confirm the absence or presence of the mutated residues
(data not shown).
Discussion
The subcellular localisation of PC2 has been the subject of some debate due to different findings
in different experimental systems. In summary, PC2 has been localised to the ER, plasma
membrane (basolateral or apical) and primary cilia: functional channel activity at all these sites
has been documented. For instance, endogenous surface PC2 currents have been measured in
human syncytiotrophoblasts, mIMCD3 and LLCPK1 cells. (10,12,13)In addition, flow-
activated Ca2+ currents attributable to ciliary PC2 channels are present in immortalised mouse
collecting duct cells. (11)Similarly, ER microsomes isolated from LLCPK1 stably transfected
with heterologous PKD2 demonstrate PC2 currents. (14)Differences in cell type,
differentiation status and culture conditions may account for some of these differences. (12,
21)Nevertheless, it is unclear whether the loss of PC2 function within a specific compartment
is especially critical for the maintenance of tubular differentiation and morphology.
Subcellular membrane fractionation has shown that most of native PC2 (∼90%) is located in
the ER with smaller amounts in the Golgi and plasma membrane. (8,21)The plasma membrane
component (including ciliary membrane) can vary but probably accounts for ∼5-10% of total
cellular PC2, as indicated by previous reports and from our current study. This has been
demonstrated using a variety of techniques such as membrane fractionation, surface
biotinylation and live cell surface antibody labelling. (8,12,13,21)The surface fraction of PC2
is reported to be increased by the use of proteosome inhibitors and/or chemical chaperones in
some experimental systems. (22)However it is variable and can be difficult to detect by
immunolabelling. Nonetheless, it could represent the active population of PC2 channels, either
as homodimers or as heterodimers with PC1 or other membrane proteins such as TRP channel
subunits. (7,8)It is tempting to speculate that the targeting, anterograde or retrograde trafficking
of PC2, from the ER to the plasma membrane or primary cilium are significant rate-limiting
steps. The situation may be analogous to that of the epithelial sodium channel ENaC which is
also found mainly as an ER resident and yet exerts its major function at the plasma membrane.
(23)Similarly, the surface expression and activity of the TRP channel, TRPC5, can be induced
by growth factors. (24)This could be an alternative mechanism for regulating TRP channel
activity since many TRP channels are constitutively active. (25)
In a recent study, the retrograde trafficking of PC2 was shown to be dependent on
phosphorylation at a single C-terminal residue, Ser812, within an acidic cluster motif (SEED).
(17)Phosphorylation at this casein kinase 2 (CK2) site enabled PC2 to be recognised by
phosphofurin acidic cluster sorting protein-1 and -2 (PACS-1 and PACS-2), two adaptor
proteins which in turn mediate the retrograde trafficking of PC2 from the plasma membrane
to the Golgi, and Golgi to ER respectively.
Only one previous study has examined the phosphorylation of PC2, concluding that a single
residue (Ser812) within its C-terminal domain could be metabolically labelled in vitro. (16)
Nonetheless, our results indicate that phosphorylation of PC2 can also occur within the N-
terminal domain at a different residue (Ser76) which forms part of a highly conserved GSK-3
recognition consensus sequence. Its functional importance was further demonstrated by the
loss of surface PC2 in MDCK and mIMCD-3 cells in the presence of chemical GSK-3
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inhibitors. Significantly, we found that the phenotype induced by a pkd2ATGMO to zebrafish
(cystic pronephros, body curvature, and hydrocephalus) was completely rescued by capped
wild-type but not by a S76A/S80A PKD2 mutant mRNA indicating that GSK-3 modification
of PC2 is functionally important for the maintenance of normal glomerular and tubular
morphology (Fig 4).
It seems likely that there exists a different targeting ciliary motif for PC2 since GSK-3 inhibition
had no effect on PC2 localisation in primary cilia (Fig 3A). Whatever the significance of ciliary
PC2 in zebrafish pronephric kidney, our results suggest that the plasma membrane localisation
of PC2 is itself functionally important. The dynamic control of PC2 insertion into the plasma
membrane by phosphorylation at two specific residues (Ser76 or Ser812) provides further
evidence of how tightly the activity of this channel is regulated (Fig 3C). Finally, mutation of
both Ser76 and Ser812 residues was insufficient to completely abolish phospholabelling of PC2




All chemicals were purchased from Sigma (Poole, UK) unless otherwise stated. MDCK II cells
were a gift of Prof R Montesano (Geneva, Switzerland) and HEK-293 cells were provided by
Dr S Ponnambalam (Leeds, UK). A mouse mAb to desmoplakin (clone 115F) was provided
by Professor DR Garrod (Manchester, UK). A rat mAb to ZO-1 was obtained from the
Developmental Studies Hybridoma Bank, University of Iowa, USA. Antibodies to E-cadherin
and calnexin were purchased from BD Transduction Labs (Cowley, Oxford, UK). The PC2
antibodies p30 and 1A11 (gift of Dr G Wu, Vanderbilt, USA) which recognise the C-terminal
258 amino acids of human PC2 have been previously described. (26,27)
Cell Culture and Transfection
HEK-293, MDCK and mIMCD3 cells were cultured in DMEM supplemented with 10% fetal
bovine serum. Transient transfection was carried out on cells cultured to 90% confluency using
Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Conditionally
immortalised mouse collecting duct cells (M8) were cultured at 33°C in DMEM/ F12
supplemented with 5% Nuserum and recombinant mouse gamma-interferon (Boehringer
Mannheim, Germany) to activate T antigen expression as previously described. (8)
32P Metabolic Labelling
Cells were cultured to 90% confluency prior to labelling. Cells were washed 3x phosphate
deficient DMEM to remove any residual phosphate and incubated for 4 h in phosphate deficient
medium containing inorganic 32P at 50 μCi/ml. The radio-labelling was terminated by washing
the cells twice in with ice-cold PBS. For immuno-precipitation (IP), cells were lysed in IP
buffer (150 mM NaCl, 25 mM NaPO4 pH 6.9, 1% TX100, 0.5% NP40 containing 50 mM
sodium fluoride, 2 mM sodium orthovanadate and complete protease inhibitors) for 1h at 4°C
on a rotator or with 1% SDS. (8) Lysates obtained with 1% SDS were diluted ten-fold with IP
buffer (final SDS concentration 0.1% SDS) prior to IP. The supernatants recovered by
centrifugation were then immuno-precipitated using the antibodies described and
immunocomplexes resolved on SDS-PAGE. The gels were dried and subjected to auto-
radiography.
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Lambda Protein Phosphatase Assay
Following transfection cells were cultured for 48 h and lysed in IP buffer containing complete
protease inhibitors for 1 h at 4°C on a rotator. Dephosphorylation was carried out by incubating
50 μg total cell lysates with 200 U Lambda (λ) protein phosphatase (New England Biolabs)
for 30, 60 and 90 min at 30°C in reaction buffer (50mM Tris-HCl, 0.1 mM EDTA, 5 mM
dithiothreitol, 0.01% Brij 35 pH 7.5) supplemented with 2 mM MnCl2. Reactions were
terminated by addition of an equal volume of 2x sample loading buffer. Lysates were analysed
by SDS-PAGE and western blotting as previously described. (8)
Site Directed Mutagenesis
Site directed mutagenesis was carried out using the Quickchange site-directed mutagenesis kit
(Stratagene, UK) according to the manufacturers instructions. The full-length PKD2 plasmids,
PKD2Pk and TM4FL (gift of Prof S Somlo, Yale, USA) have been described and were used
as templates. (18,26)PAGE purified mutagenic primers were synthesised by Sigma Genosys
(UK) - primer sequences are available on request.
Generation of PC2 truncation mutants
We introduced the naturally occurring truncating PKD2 mutation R742X by polymerase chain
reaction (PCR) using the PKD2Pk plasmid as a template. An influenza virus hemagglutinin
(HA) protein epitope tag and an in-frame stop codon were included in the reverse primer.
PKD2 cDNAs containing codons 1-224 (full N-terminus) and truncations 1-178 and 1-118
were generated by PCR amplification from the TM4FL template using forward and reverse
primers containing XbaI and HindIII linkers respectively. The forward primer containing the
XbaI site also contained an HA tag sequence. PCR products were gel purified and subcloned
into the XbaI and HindIII sites of the expression plasmid pcDNA3.1 (−). All cDNA constructs
were confirmed by direct sequencing. PCR primer sequences are available on request.
Cell Surface Biotinylation
Cells were cultured to confluency in 10cm dishes, washed three times with PBS and incubated
for 30 min with 1 mg/ml sulpho-NHS-LC-Biotin in PBS at 4°C. Cells were rinsed twice with
PBS containing 100 mM glycine and excess biotin quenched by further incubation for 20 min
with PBS containing 100 mM glycine and 0.1% BSA. Cells were rinsed twice with PBS and
lysed by the addition of 500 μl lysis buffer (50 mM Tris, 500 mM NaCl, 5mM EDTA, 1%
Tx100, pH 7.5) for 1 h at 4°C. Equal amounts of cell lysate were incubated with 100 μl
streptavidin beads overnight at 4°C. Beads were washed three times each with lysis buffer,
high salt buffer (50 mM Tris, 500 mM NaCl, 0.1% Tx100) and non-salt buffer (10 mM Tris,
pH 7.5) before being resuspended in 40 μl 2 × SDS sample buffer. Samples were analysed by
SDS-PAGE and western blotting using the antibodies described.
Immunofluorescence
Cells were grown on glass coverslips and were fixed with ice-cold methanol:acetone (70:30)
at 4°C for 10 min followed by air drying for 10 min. Blocking was carried out for 15 min with
5% BSA/PBS and primary antibodies were incubated overnight at 4°C in 1% BSA/PBS.
Controls included cells stained with primary antibody omitted, an irrelevant IgG1 mAb
(Serotec, Kidlington, UK) or a non-immune rabbit IgG fraction (Dako, Ely, UK). Antibody
binding was visualised using FITC-conjugated goat ant-mouse IgG and Texas Red or FITC
labelled goat anti-rabbit secondary antibodies. Slides were viewed using an Olympus Imaging
Systems inverted IX71 microscope configured for multi-fluorescence image capture. Images
were acquired and analysed using SimplePCI imaging software (Compix, Inc).
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Wild-type zebrafish AB strain were maintained and raised as described. (28)Embryos were
kept in E3 solution and staged according to hours post-fertilization (hpf). (29) An antisense
morpholino oligonucleotide (MO, Gene Tools LLC Philomath, Oregon, USA) was used to
block zebrafish pkd2 translation as described (hi4166). (20) Final pkd2ATGMO concentration
in the cytoplasm was estimated as 100 nM. The rescue experiments were carried out by co-
injecting 50 pg of in vitro transcribed capped mRNA encoding human PKD2-wt or PKD2-
S76A/S80A. Capped RNAs were synthesized using a mMessage mMachine T7 kit (Ambion,
Austin, Texas, USA). Embryos were microinjected at the one cell stage in the yolk in 100mM
KCl, 0.1% Phenol Red and 10mM HEPES. Nested RT-PCR primers were used to detect human
PKD2-wt or PKD 2-S76A/S80A to confirm expression in the injected zebrafish embryos.
Amplification of β-actin was performed as a positive control. (30)Primers designed to detect
human PKD2 are hPKD2-13F1: AGTCGCGTGCAGCCTCAG, hPKD2-358R1:
GGCGCCACTCTACGTCCAT, hPKD2-152F2: GCCTGGAGATCGAGATGC,
hPKD2-323R2: CCTTCTTCCCCTTCCACCT. Embryos were fixed at 72hpf in 1.5%
Glutaraldehyde, 1% Paraformaldehyde, 70mM NaPO4 pH 7.2, 3% Sucrose overnight at 4°C,
embedded in glycolmethacrylate (JB-4; Polyscience, Warrington, Pennsylvania, USA) by
following the manufacturer's instructions and sectioned at 4μm using HM325 (Richard-Allan
Scientific). Slides were stained with Methylene Blue and Azure II. (31)Whole mount images
are taken by Leica MZ125 and section images are taken by Nikon E500 and analyzed by Spot
v. 4.2 program.
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Fig 1. PC2 is phosphorylated at both its N- and C-termini
(A). Endogenous PC2 was shown to be phosphorylated by immuno-precipitation of 32P
labelled samples derived from mouse collecting duct cells. The rabbit polyclonal antibody p30
and non-immune rabbit serum (NIS) control was used for IP.
(B). A diagram of PC2 full length and R742X truncated constructs showing the predicted sites
of phosphorylation within the C-terminus which were mutated for phosphorylation analysis.
(C). Immunoprecipitation of PC2 constructs from transfected HEK-293 cell lysates was carried
out following metabolic labelling with 32P. Labelled constructs were immunoprecipitated with
antibodies raised to a pkTAG epitope tag or antibodies raised to an HA epitope tag (R742X).
All C-terminal mutants as well as wild type PC2 were shown to be phosphorylated. However
the 5 site combined mutant showed a reduced level of phosphorylation compared to the single
site mutants. The R742X construct was also labelled with 32P.
(D). A diagram showing the constructs generated to assess phosphorylation of the N-terminus
of PC2.
(E). Cell lysates from HEK-293 cells were treated with λ phosphatase for 0, 30 and 60 min and
analysed by western blotting with HA tag specific antibodies. A clear doublet band is seen in
both L224X transfected cells (upper panel) and W118X transfected cells (lower panel). The
upper band disappears following incubation with the enzyme demonstrating that it is due to
phosphorylation.
(F). Immunoprecipitation of PC2 N-terminal constructs truncated at amino acids 118, 178 and
224 was carried out following metabolic labelling with 32P in transfected HEK-293 cells.
Labelled constructs were immunoprecipitated with antibodies raised to an HA epitope tag,
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separated on 5% SDS-PAGE and analysed by autoradiography. All three constructs were
shown to be phosphorylated.
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Fig 2. GSK-3 mediates phosphorylation of the N-terminus of PC2 at Ser76
(A). A diagram of PC2 N-terminal constructs showing the predicted sites of phosphorylation
which were mutated for phosphorylation analysis. (B). To confirm the site responsible for N-
terminal phosphorylation, single site mutants of L224X were immunoblotted with an antibody
directed to the HA epitope tag to detect the presence of a phosphorylated banding pattern (upper
panel). Loss of the upper phosphorylated band was only seen in cells transfected with the S76A
mutant construct. Immunoprecipitation of N-terminal mutants following metabolic labelling
with 32P in transfected HEK-293 cells (lower panel) confirmed this result demonstrating that
Ser76 is responsible for N-terminal PC2 phosphorylation. (C). L224X and S76A mutants were
transfected into IMCD3, CHO-K1 and MDCK cells. Lysates were immunoblotted with an
antibody directed to the HA epitope tag to detect the presence of a phosphorylated banding
pattern. Phosphorylation was absent as seen by the loss of the upper phosphorylated band in
cells transfected with the S76A mutant construct but its presence in wild type controls.
(D). Sequence data for various PC2 homologues aligned by Clustal W indicate that a GSK-3
recognition sequence is conserved across species down to lower vertebrates. The accession
numbers for each sequence are as follows: Q13563 (Homo sapiens), O35245 (Mus musculus),
XP573552 (Rattus norvegicus), Q5ZM00 (Gallus gallus), Q6IVV8 (Danio rerio).
(E). To confirm that phosphorylation at Ser76 is mediated by GSK-3, a number of GSK-3
specific inhibitors, (i) LiCl (10mM) (ii) BIO (2′Z,3′E)-6-Bromoindirubin-3′-oxime (5 μM;
Calbiochem, UK) (iii) SB 216763 (10 μM; Tocris, UK) and (iv) SB 415286 (40 μM; Tocris,
UK) were added to HEK-293 cells transfected with L224X for 16 h at the concentrations
indicated. Lysates were immunoblotted with an antibody directed to the HA epitope tag to
detect the presence of a phosphorylated banding pattern. Phosphorylation was absent as seen
by the loss of the upper phosphorylated band in cells treated with each inhibitor but present in
untreated controls.
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(F). HEK-293 cells were transfected with L224X or L224X containing a mutation of Ser80 to
alanine. Lysates were immunoblotted with an antibody directed to the HA epitope tag to detect
the presence of a phosphorylated banding pattern.
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Fig 3. Inhibition of GSK-3 alters the cellular localisation of PC2
(A). Immunofluoresence staining was carried out on MDCK cells treated with 10 mM LiCl (i)
or 40 μM SB 415286 (ii, iii, iv, v, vi) for 16 h compared to control untreated cells. In the
presence of LiCl or SB 415286, endogenous PC2 (detected with affinity-purified p30)
redistributes from a lateral plasma membrane pool (arrows) into an intracellular compartment
in MDCK cells (i, ii) with no change in ciliary localisation (iii, arrows). The distribution of
ZO-1 (iv), E-cadherin (v) and desmoplakin (vi) remained unchanged after GSK-3 inhibition.
The insets in (iii) show colocalisation of the PC2 signal (red) with acetylated tubulin (green)
confirming that cilia localisation of PC2 did not change after inhibition of GSK-3.
(B). Cell surface biotinylation was carried out on mIMCD3 and MDCK cells treated with 40
μM SB 415286 for 16 h compared to control untreated cells. Western blotting with a specific
anti-PC2 antibody (1A11) was carried out on biotinylated protein bound to and eluted from
streptavidin beads. The blots show that a fraction (∼10%) of PC2 is present at the cell surface
in control cells but is greatly reduced (∼1.5%) in cells treated with the inhibitor.
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Immunoblotting with antibodies directed to an ER resident protein, calnexin and a cell surface
marker, Na+K+ATPase show that only cell surface proteins have been biotinylated and these
are unaffected by treatment with the inhibitor.
(C). Diagram to illustrate the anteograde (mediated by Ser76) and retrograde (mediated by
Ser812) trafficking of PC2 between different subcellular compartments and the lateral plasma
membrane. The signals that regulate PC2 trafficking to the primary cilium are not known but
appear to be independent of GSK-3 phosphorylation at Ser76. PC2 is displayed as a
homotetramer on the basis of biochemical characterisation and by analogy to other TRP
channels (8). However, PC2 can also form heterodimers with PC1 and TRPC1 (see text).
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Fig 4. Human wild type but not a human PKD2-S76A/S80A mRNA can rescue the pkd2 ATGMO
phenotype in zebrafish
(A) 72 hpf zebrafish embryos injected with a control antisense MO have normal body
morphology as described. (30)Histology section of a 72 hpf embryo pronephric kidney showing
glomerulus (glm) and pronephric tubule (pt). (B) pkd2ATGMO injected embryos showing
pronephric kidney cysts, body axis curvature and hydrocephalus. Cystic dilatation of
pronephric tubules and glomerulus lined with stretched epithelium are clearly visible. (C) Co-
injection of 50pg human PKD2 mRNA suppresses formation of pronephric kidney cysts, body
axis curvature and hydrocephalus. (D) Co-injection of 50pg human PKD2-S76A/S80A mRNA
cannot rescue pronephric cysts and hydrocephalus caused by pkd2ATGMO. Body axis
curvature is slightly rescued by human PKD2-S76A/S80A mRNA. (E) RT-PCR analysis for
human PKD2 (upper panel) and β-actin (lower panel) mRNA expression in 72 hpf embryos.
DNA marker (lane M), control embryos (lane C), pkd2ATGMO injected embryos (lane MO),
pkd2ATGMO and human PKD2 mRNA injected embryos (lane MO+hPKD2), and
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pkd2ATGMO and human PKD2-S76A/S80A mRNA injected embryos (lane MO+hPKD2-
S76A/S80A) were analyzed with RT-PCR primers that generate a 172-bp product representing
the N-terminus of human PKD2. Amplification of β-actin mRNA (lower panel) was used as a
positive control.
Streets et al. Page 18
Hum Mol Genet. Author manuscript; available in PMC 2008 June 11.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
